NVS  Novartis Ag




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.45 (-0.52%)

Growth Price

Overvalued by 25.40%

Stability Price

Overvalued by 74.56%

Company Metrics

  • P/E 11.56
  • P/S 4.07
  • P/B 2.70
  • EPS 7.43
  • Cash ROIC 12.42%
  • Cash Ratio 0.51
  • Dividend 2.67 / 3.08 %
  • Avg. Vol. 1.85M
  • Shares 2.40B
  • Market Cap. 205.92B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Novartis AG (ADR) Entresto Clinches EU approval
Business Finance News - Nov 25, 2015
The Novartis (NYSE:NVS) drug Entresto has won approval from EU Regulators to treat chronic heart disease with a low ejection fraction.
Novartis Heart Failure Drug Entresto Approved By European Commission — Shares ... - The Articlebasis.com
Trade of the Day: It's Not Too Late to Short NVS Stock
Investorplace.com - Nov 24, 2015
Novartis AG (ADR) (NVS) - I last featured NVS stock as the Trade of the Day on Oct. 1, recommending traders sell shares short at $95 with a downside target of $85.
How Analysts Rated Novartis AG (ADR) (NYSE:NVS) Last Week? - FinancialMagazin.com
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Business Finance News - Nov 23, 2015
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Novartis AG (ADR) And Roche May Have To Wait Longer For “Outcome-Based ...
Business Finance News - Nov 13, 2015
The outcome-based drug pricing model is becoming a dream for Novartis AG (ADR) (NYSE:NVS) and Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY).
Here's Why Novartis AG (ADR) Fared Better Than Others
Bidness ETC - Oct 21, 2015
Novartis AG ADR (NYSE:NVS) has signed three deals to expand its reach in the immune-oncology market. On Wednesday, Novartis announced that it had acquired Admune Therapeutics, a cancer drug maker.
Novartis (NVS) Strengthens It's Pipeline With Admune Therapeutics & XOMA - CNA Finance (press release)
Trade of the Day: NVS Stock Not Making the Cut – Sell Now
Investorplace.com - Oct 1, 2015
Novartis AG (ADR) (NVS) - This company is a leading provider of pharmaceuticals, generic drugs and health care products for consumers and animals.
Novartis AG (ADR) (NYSE:NVS) Plans To Provide Cheap Medicines To Poorer Countries - InvestCorrectly
Novartis AG (ADR) to Decline On Q3 Earnings
Bidness ETC - Oct 27, 2015
The share price for Novartis AG ADR (NYSE:NVS) is expected to decline as the drug maker reported lower-than-expected sales and earnings for the third quarter of this fiscal (3QFY15).
Revenue Update on Novartis AG (NYSE:NVS) - News Watch International
Hot Healthcare Stocks: Novartis AG (NVS), Spectrum Pharmaceuticals(SPPI), St ... - Techsonian (press release)
Notable Runners: Biogen Inc (NASDAQ:BIIB), Novartis AG (ADR) (NYSE:NVS ...
News Oracle - Nov 25, 2015
Novartis AG (ADR) (NYSE:NVS) lost -0.30% and closed the last trading session at $86.39. The market capitalization of the company is $238.26 billion with the total traded volume of the company is 1.62 million.
Novartis AG (ADR) On Collision Course With Amgen, Inc. Again With Another ...
Bidness ETC - Oct 2, 2015
Novartis AG ADR (NYSE:NVS) and Amgen Inc. (NASDAQ:AMGN) seem to be on a collision course again as Novartis is on track to get another biosimilar candidate approved by the US Food and Drug Administration (FDA).
Novartis AG (ADR) (NVS) Stock Update: September Begins With Multiple Deals And ...
Bidness ETC - Sep 4, 2015
Novartis AG (ADR) (NYSE:NVS) has seen an eventful first week of September. The company struck a partnership deal with biotech giant Amgen, Inc. (NASDAQ:AMGN) and won regulatory approvals for several drugs in both the US and Europe - all during the ...